Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians
The DOI matches its Crossref record; 370 of the 370 references it cites were found in a registry or an index.
Abstract
Description: This guideline updates the 2008 American College of Physicians (ACP) recommendations on treatment of low bone density and osteoporosis to prevent fractures in men and women. This guideline is endorsed by the American Academy of Family Physicians. Methods: The ACP Clinical Guidelines Committee based these recommendations on a systematic review of randomized controlled trials; systematic reviews; large observational studies (for adverse events); and case reports (for rare events) that were published between 2 January 2005 and 3 June 2011. The review was updated to July 2016 by using a machine-learning method, and a limited update to October 2016 was done. Clinical outcomes evaluated were fractures and adverse events. This guideline focuses on the comparative benefits and risks of short- and long-term pharmacologic treatments for low bone density, including pharmaceutical prescriptions, calcium, vitamin D, and estrogen. Evidence was graded according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Target Audience and Patient Population: The target audience for this guideline includes all clinicians. The target patient population includes men and women with low bone density and osteoporosis. Recommendation 1: ACP recommends that clinicians offer pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab to reduce the risk for hip and vertebral fractures in women who have known osteoporosis. (Grade: strong recommendation; high-quality evidence). Recommendation 2: ACP recommends that clinicians treat osteoporotic women with pharmacologic therapy for 5 years. (Grade: weak recommendation; low-quality evidence). Recommendation 3: ACP recommends that clinicians offer pharmacologic treatment with bisphosphonates to reduce the risk for vertebral fracture in men who have clinically recognized osteoporosis. (Grade: weak recommendation; low-quality evidence). Recommendation 4: ACP recommends against bone density monitoring during the 5-year pharmacologic treatment period for osteoporosis in women. (Grade: weak recommendation; low-quality evidence). Recommendation 5: ACP recommends against using menopausal estrogen therapy or menopausal estrogen plus progestogen therapy or raloxifene for the treatment of osteoporosis in women. (Grade: strong recommendation; moderate-quality evidence). Recommendation 6: ACP recommends that clinicians should make the decision whether to treat osteopenic women 65 years of age or older who are at a high risk for fracture based on a discussion of patient preferences, fracture risk profile, and benefits, harms, and costs of medications. (Grade: weak recommendation; low-quality evidence).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Affected trial reports were cited in nine effectiveness reviews and clinical guidelines (one published in Scotland, the others in the USA), for stroke,49 fracture prevention50–55 and fall and injury prevention.56”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [55]
In the citing paper
“The updated 2017 American College of Physicians’ guidelines55 (74 citations, October 2018) includes two of the affected trial reports on 2.5 mg daily risedronate13 16 in its overview of the evidence for the use of risedronate from the AHRQ review,54 but does not discuss the specific issue of the lower dose of risedronate.”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [55]
In the citing paper
“Fracture risk approximately doubles with every SD T-score reduction.137,138”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [138]
Citations
Cites
9 retracted
Sato, Y., Iwamoto, J., Kanoko, T., & Satoh, K. (2005) · Cerebrovascular Diseases · doi:10.1159/000087203 · Cited by 410
RetractedWimalawansa, S. J. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00029-1 · Cited by 186
RetractedIshida, Y., & Kawai, S. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.05.019 · Cited by 132
RetractedSato, Y., Manabe, S., Kuno, H., & Oizumi, K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.1.64 · Cited by 131
Retracted(2007) · Neurology · doi:10.1212/01.wnl.0000257089.50476.92 · Cited by 90 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetractedSato, Y., Kanoko, T., Satoh, K., & Iwamoto, J. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1737 · Cited by 69 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetractedSatō, Y., Metoki, N., Iwamoto, J., & Satoh, K. (2003) · Neurology · doi:10.1212/01.wnl.0000078892.24356.90 · Cited by 51
RetractedSatō, Y., Kuno, H., Kaji, M., Saruwatari, N., & Oizumi, K. (1999) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/00002060-199909000-00008 · Cited by 38
RetractedAnti-Fracture Efficacy of Risedronic Acid in Men: A Meta-Analysis of Randomized Controlled Trials
Zhong, Z., & Chen, J. (2009) · Clinical Drug Investigation · doi:10.2165/00044011-200929050-00007 · Cited by 30 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetractedWriting Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Clinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149 · cited 10×
“Another risk factor for osteoporotic fracture is long-term use of certain medications, the most commonly implicated being glucocorticoids, anticoagulants, anticonvulsants, aromatase inhibitors, cancer chemotherapeutic drugs, and gonadotropin-releasing hormone agonists (5).”
BackgroundInfluentialBlack, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846 · cited 8×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialDenosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Vitamin D3and Calcium to Prevent Hip Fractures in Elderly Women
Chapuy, M. C., Arlot, M. E., Duboeuf, F., Brun, J., Crouzet, B., Arnaud, S., Delmas, P. D., & Meunier, P. J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212033272305 · Cited by 2,950
Harris, S. T. (1999) · JAMA · doi:10.1001/jama.282.14.1344 · Cited by 2,475 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialLiberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,288 · cited 8×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialCummings, S. R. (1998) · JAMA · doi:10.1001/jama.280.24.2077 · Cited by 2,277 · cited 8×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialDawson-Hughes, B., Harris, S. S., Krall, E. A., & Dallal, G. E. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371003 · Cited by 2,277
Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa074941 · Cited by 2,003
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Calcium plus Vitamin D Supplementation and the Risk of Fractures
Jackson, R. D., LaCroix, A. Z., Gass, M., Wallace, R. B., Robbins, J., Lewis, C. E., Bassford, T., Beresford, S. A. A., Black, H. R., Blanchette, P., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055218 · Cited by 1,883
Delmas, P. D., Bjarnason, N. H., Mitlak, B. H., Ravoux, A.-C., Shah, A. S., Huster, W. J., Draper, M., & Christiansen, C. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712043372301 · Cited by 1,637
Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialFracture Prevention With Vitamin D Supplementation: A Meta-analysis of Randomized Controlled Trials
Bischoff-Ferrari, H. A., Willett, W. C., Wong, J. B., Giovannucci, E., Dietrich, T., & Dawson-Hughes, B. (2005) · JAMA · doi:10.1001/jama.293.18.2257 · Cited by 1,530
Black, D. M., Schwartz, A. V., Ensrud, K. E., Cauley, J. A., Levis, S., Quandt, S. A., Satterfield, S., Wallace, R. B., Bauer, D. C., Palermo, L., et al. (2006) · JAMA · doi:10.1001/jama.296.24.2927 · Cited by 1,407 · cited 1×
“Bone Mineral Density Moderate-quality evidence from post hoc analysis of 1 RCT showed that low femoral neck BMD did not predict the effect of alendronate on clinical vertebral or nonvertebral fracture risk (240).”
BackgroundSanders, K. M., Stuart, A. L., Williamson, E. J., Simpson, J. A., Kotowicz, M. A., Young, D., & Nicholson, G. C. (2010) · JAMA · doi:10.1001/jama.2010.594 · Cited by 1,381
Trivedi, D. P., Doll, R., & Khaw, K. T. (2003) · BMJ · doi:10.1136/bmj.326.7387.469 · Cited by 1,270
Tang, B. M., Eslick, G. D., Nowson, C., Smith, C., & Bensoussan, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61342-7 · Cited by 1,248
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Bolland, M. J., Avenell, A., Baron, J. A., Grey, A., MacLennan, G. S., Gamble, G. D., & Reid, I. R. (2010) · BMJ · doi:10.1136/bmj.c3691 · Cited by 1,099
Alendronate for the Treatment of Osteoporosis in Men
Orwoll, E., Ettinger, M., Weiss, S., Miller, P., Kendler, D., Graham, J., Adami, S., Weber, K., Lorenc, R., Pietschmann, P., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008313430902 · Cited by 973 · cited 8×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialIntravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., Widmer, A., Devogelaer, J.-P., Kaufman, J.-M., Jaeger, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011807 · Cited by 877 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialBolland, M. J., Grey, A., Avenell, A., Gamble, G. D., & Reid, I. R. (2011) · BMJ · doi:10.1136/bmj.d2040 · Cited by 851
Orwoll, E., Scheele, W., Paul, S., Adami, S., Syversen, U., Diez-Perez, A., Kaufman, J.-M., Clancy, A., & Gaich, G. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.1.9 · Cited by 776
Bischoff-Ferrari, H. A., Willett, W. C., Wong, J. B., Stuck, A. E., Staehelin, H. B., Orav, E. J., Thoma, A., Kiel, D. P., & Henschkowski, J. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.600 · Cited by 776
Cummings, S. R., Karpf, D. B., Harris, F., Genant, H. K., Ensrud, K., LaCroix, A. Z., & Black, D. M. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01124-x · Cited by 752
Black, D. M., Reid, I. R., Boonen, S., Bucci-Rechtweg, C., Cauley, J. A., Cosman, F., Cummings, S. R., Hue, T. F., Lippuner, K., Lakatos, P., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1494 · Cited by 700 · cited 1×
“Another study on zoledronic acid showed no difference for clinical vertebral fractures, hip fractures, nonvertebral fractures, or all clinical fractures in women who continued to receive the drug for 3 versus 6 years (369).”
BackgroundBolland, M. J., Barber, P. A., Doughty, R. N., Mason, B., Horne, A., Ames, R., Gamble, G. D., Grey, A., & Reid, I. R. (2008) · BMJ · doi:10.1136/bmj.39440.525752.be · Cited by 691
Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women
Chapuy, M. C., Arlot, M. E., Delmans, P. D., & Meunier, P. J. (1994) · BMJ · doi:10.1136/bmj.308.6936.1081 · Cited by 673
Avenell, A., Gillespie, W. J., Gillespie, L. D., & O'Connell, D. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000227.pub3 · Cited by 667
SMITH, M. R., EASTHAM, J., GLEASON, D. M., SHASHA, D., TCHEKMEDYIAN, S., & ZINNER, N. (2003) · Journal of Urology · doi:10.1097/01.ju.0000063820.94994.95 · Cited by 650
Lips, P., Graafmans, W. C., Ooms, M. E., Bezemer, P. D., & Bouter, L. M. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-4-199602150-00003 · Cited by 646
Cohen, S., Levy, R. M., Keller, M., Boling, E., Emkey, R. D., Greenwald, M., Zizic, T. M., Wallach, S., Sewell, K. L., Lukert, B. P., et al. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199911)42:11<2309::aid-anr8>3.0.co;2-k · Cited by 613 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialPols, H. A. P., Felsenberg, D., Hanley, D. A., Štepán, J., Muñoz-Torres, M., Wilkin, T. J., Qin-sheng, G., Galich, A. M., Vandormael, K., Yates, A. J., et al. (1999) · Osteoporosis International · doi:10.1007/pl00004171 · Cited by 593 · cited 8×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialReid, D. M., Hughes, R. A., Laan, R. F. J. M., Sacco-Gibson, N. A., Wenderoth, D. H., Adami, S., Eusebio, R. A., & Devogelaer, J.-P. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.1006 · Cited by 592
Pfeifer, M., Begerow, B., Minne, H. W., Abrams, C., Nachtigall, D., & Hansen, C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.1113 · Cited by 591
Treatment of Postmenopausal Osteoporosis with Calcitriol or Calcium
Tilyard, M. W., Spears, G. F. S., Thomson, J., & Dovey, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202063260601 · Cited by 575
Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women
Chlebowski, R. T., Anderson, G. L., Gass, M., Lane, D. S., Aragaki, A. K., Kuller, L. H., Manson, J. E., Stefanick, M. L., Ockene, J., Sarto, G. E., et al. (2010) · JAMA · doi:10.1001/jama.2010.1500 · Cited by 567 · cited 1×
“Another study showed that estrogen plus progestin therapy was associated with more invasive breast cancer, more node-positive tumors, and more deaths due to breast cancer than placebo (354).”
BackgroundChapuy, M. C., Pamphile, R., Paris, E., Kempf, C., Schlichting, M., Arnaud, S., Garnero, P., Garnero, P., & Meunier, P. J. (2002) · Osteoporosis International · doi:10.1007/s001980200023 · Cited by 549
Boonen, S., Lips, P., Bouillon, R., Bischoff-Ferrari, H. A., Vanderschueren, D., & Haentjens, P. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1404 · Cited by 537
Porthouse, J., Cockayne, S., King, C., Saxon, L., Steele, E., Aspray, T., Baverstock, M., Birks, Y., Dumville, J., Francis, R., et al. (2005) · BMJ · doi:10.1136/bmj.330.7498.1003 · Cited by 535
Wallach, S., Cohen, S., Reid, D. M., Hughes, R. A., Hosking, D. J., Laan, R. F., Doherty, S. M., Maricic, M., Rosen, C., Brown, J., et al. (2000) · Calcified Tissue International · doi:10.1007/s002230001146 · Cited by 513 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialEffect of Calcium Supplementation on Bone Loss in Postmenopausal Women
Reid, I. R., Ames, R. W., Evans, M. C., Gamble, G. D., & Sharpe, S. J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302183280702 · Cited by 512
Pfeifer, M., Begerow, B., Minne, H. W., Suppan, K., Fahrleitner-Pammer, A., & Dobnig, H. (2009) · Osteoporosis International · doi:10.1007/s00198-008-0662-7 · Cited by 510
Silverman, S. L., Christiansen, C., Genant, H. K., Vukicevic, S., Zanchetta, J. R., de Villiers, T. J., Constantine, G. D., & Chines, A. A. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080710 · Cited by 508 · cited 1×
“92) (122, 341, 345, 347) and cerebrovascular death (OR, 1.”
Wells, G. A., Cranney, A., Peterson, J., Boucher, M., Shea, B., Welch, V., Coyle, D., & Tugwell, P. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003376.pub3 · Cited by 499
Saag, K. G., Zanchetta, J. R., Devogelaer, J., Adler, R. A., Eastell, R., See, K., Krege, J. H., Krohn, K., & Warner, M. R. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24879 · Cited by 493 · cited 1×
“Glucocorticoid Treatment Moderate-quality evidence showed that alendronate, risedronate, and teriparatide reduced fracture risk in patients taking glucocorticoids (30, 219).”
BackgroundPrevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure
Lo, J. C., O'Ryan, F. S., Gordon, N. P., Yang, J., Hui, R. L., Martin, D., Hutchinson, M., Lathon, P. V., Sanchez, G., Silver, P., et al. (2010) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.03.050 · Cited by 493
Prevention of Bone Loss with Alendronate in Postmenopausal Women under 60 Years of Age
Hosking, D., Chilvers, C. E. D., Christiansen, C., Ravn, P., Wasnich, R., Ross, P., McClung, M., Balske, A., Thompson, D., Daley, M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802193380801 · Cited by 488
Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men
Avenell, A., Mak, J. C., & O'Connell, D. L. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000227.pub4 · Cited by 482
Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women
Chlebowski, R. T., Kuller, L. H., Prentice, R. L., Stefanick, M. L., Manson, J. E., Gass, M., Aragaki, A. K., Ockene, J. K., Lane, D. S., Sarto, G. E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807684 · Cited by 472 · cited 1×
“One subsequent assessment of the trial showed that the higher incidence of breast cancer decreased after therapy was discontinued (353).”
BackgroundPrince, R. L., Devine, A., Dhaliwal, S. S., & Dick, I. M. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.8.869 · Cited by 453
II. Meta-Analysis of Alendronate for the Treatment of Postmenopausal Women
Cranney, A., Wells, G., Willan, A., Griffith, L., Zytaruk, N., Robinson, V., Black, D., Adachi, J., Shea, B., Tugwell, P., et al. (2002) · Endocrine Reviews · doi:10.1210/er.2001-2002 · Cited by 445 · cited 8×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialSarkar, S., Mitlak, B. H., Wong, M., Stock, J. L., Black, D. M., & Harper, K. D. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.1.1 · Cited by 442
Incidence of atypical nontraumatic diaphyseal fractures of the femur
Dell, R. M., Adams, A. L., Greene, D. F., Funahashi, T. T., Silverman, S. L., Eisemon, E. O., Zhou, H., Burchette, R. J., & Ott, S. M. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1719 · Cited by 441 · cited 1×
“78 per 100 000 and increased to over 100 per 100 000 in women taking the drugs for 8 years or more (256).”
BackgroundScreening for Osteoporosis: U.S. Preventive Services Task Force Recommendation Statement
U.S. Preventive Services Task Force* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-5-201103010-00307 · Cited by 436
Reid, I. R., Ames, R. W., Evans, M. C., Gamble, G. D., & Sharpe, S. J. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80310-6 · Cited by 429
Greenspan, S. L., Bone, H. G., Ettinger, M. P., Hanley, D. A., Lindsay, R., Zanchetta, J. R., Blosch, C. M., Mathisen, A. L., Morris, S. A., Marriott, T. B., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-5-200703060-00005 · Cited by 427
Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women
Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Wang, H., Liu, Y., & San Martin, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2814 · Cited by 425
Sinaki, M., Itoi, E., Wahner, H. W., Wollan, P., Gelzcer, R., Mullan, B. P., Collins, D. A., & Hodgson, S. F. (2002) · Bone · doi:10.1016/s8756-3282(02)00739-1 · Cited by 417
Wells, G. A., Cranney, A., Peterson, J., Boucher, M., Shea, B., Welch, V., Coyle, D., & Tugwell, P. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001155.pub2 · Cited by 401 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialSmith, H., Anderson, F., Raphael, H., Maslin, P., Crozier, S., & Cooper, C. (2007) · Rheumatology · doi:10.1093/rheumatology/kem240 · Cited by 400 · cited 2×
“Two RCTs evaluated vitamin D treatment in men and women and reported on fractures (136, 166).”
BackgroundVII. Meta-Analysis of Calcium Supplementation for the Prevention of Postmenopausal Osteoporosis
Shea, B., Wells, G., Cranney, A., Zytaruk, N., Robinson, V., Griffith, L., Ortiz, Z., Peterson, J., Adachi, J., Tugwell, P., et al. (2002) · Endocrine Reviews · doi:10.1210/er.2001-7002 · Cited by 399
The DIPART (vitamin D Individual Patient Analysis of Randomized Trials) Group (2010) · BMJ · doi:10.1136/bmj.b5463 · Cited by 398
Chesnut, C. H., McClung, M. R., Ensrud, K. E., Bell, N. H., Genant, H. K., Harris, S. T., Singer, F. R., Stock, J. L., Yood, R. A., Delmas, P. D., et al. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80134-x · Cited by 365 · cited 8×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialBody, J.-J., Gaich, G. A., Scheele, W. H., Kulkarni, P. M., Miller, P. D., Peretz, A., Dore, R. K., Correa-Rotter, R., Papaioannou, A., Cumming, D. C., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020334 · Cited by 365
Larsen, E. R., Mosekilde, L., & Foldspang, A. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301240 · Cited by 364 · cited 2×
“Two RCTs evaluated vitamin D treatment in men and women and reported on fractures (136, 166).”
BackgroundCorrecting calcium nutritional deficiency prevents spine fractures in elderly women
Recker, R. R., Hinders, S., Davies, K. M., Heaney, R. P., Stegman, M. R., Lappe, J. M., & Kimmel, D. B. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650111218 · Cited by 364
Kurland, E. S., Cosman, F., McMahon, D. J., Rosen, C. J., Lindsay, R., & Bilezikian, J. P. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.9.6818 · Cited by 360
Greenspan, S. L., Bone, H. G., Ettinger, M. P., Hanley, D. A., Lindsay, R. S., Zanchetta, J., Blosch, C. M., Mathisen, A. L., Morris, S. A., & Marriott, T. B. (2007) · Annals of Internal Medicine · Cited by 360
Fracture risk and zoledronic acid therapy in men with osteoporosis
Boonen, S., Reginster, J.-Y., Kaufman, J.-M., Lippuner, K., Zanchetta, J., Langdahl, B., Rizzoli, R., Lipschitz, S., Dimai, H. P., Witvrouw, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1204061 · Cited by 359 · cited 2×
“Moderate-quality evidence showed that zoledronic acid reduces radiographic vertebral fractures in osteoporotic men (95).”
BackgroundJensen, J., Lundin-Olsson, L., Nyberg, L., & Gustafson, Y. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-10-200205210-00008 · Cited by 359
Seven Years of Treatment with Risedronate in Women with Postmenopausal Osteoporosis
Mellström, D. D., Sörensen, O. H., Goemaere, S., Roux, C., Johnson, T. D., & Chines, A. A. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0286-7 · Cited by 350
Rosen, C. J., Hochberg, M. C., Bonnick, S. L., McClung, M., Miller, P., Broy, S., Kagan, R., Chen, E., Petruschke, R. A., Thompson, D. E., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040920 · Cited by 345
Bisphosphonates for Osteoporosis — Where Do We Go from Here?
Whitaker, M., Guo, J., Kehoe, T., & Benson, G. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1202619 · Cited by 337
Prince, R., Devine, A., Dick, I., Criddle, A., Kerr, D., Kent, N., Randell, A., & Price, R. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650100711 · Cited by 334
Miller, P. D., Mcclung, M. R., Macovei, L., Stakkestad, J. A., Luckey, M., Bonvoisin, B., Reginster, J.-Y., Recker, R. R., Hughes, C., Lewiecki, E. M., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050313 · Cited by 333
Brown, J. P., Kendler, D. L., McClung, M. R., Emkey, R. D., Adachi, J. D., Bolognese, M. A., Li, Z., Balske, A., & Lindsay, R. (2002) · Calcified Tissue International · doi:10.1007/s00223-002-2011-8 · Cited by 330 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialBischoff-Ferrari, H. A., Dawson-Hughes, B., Baron, J. A., Burckhardt, P., Li, R., Spiegelman, D., Specker, B., Orav, J. E., Wong, J. B., Staehelin, H. B., et al. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.5.1780 · Cited by 326
Kaufman, J.-M., Orwoll, E., Goemaere, S., San Martin, J., Hossain, A., Dalsky, G. P., Lindsay, R., & Mitlak, B. H. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1713-3 · Cited by 320
Miller, P. D., Roux, C., Boonen, S., Barton, I. P., Dunlap, L. E., & Burgio, D. E. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050817 · Cited by 318 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialLi, K., Kaaks, R., Linseisen, J., & Rohrmann, S. (2012) · Heart · doi:10.1136/heartjnl-2011-301345 · Cited by 314
Chevalley, T., Rizzoli, R., Nydegger, V., Slosman, D., Rapin, C. H., Michel, J. P., Vasey, H., & Bonjour, J. P. (1994) · Osteoporosis International · doi:10.1007/bf01623348 · Cited by 311
Cosman, F., Nieves, J., Woelfert, L., Formica, C., Gordon, S., Shen, V., & Lindsay, R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.5.925 · Cited by 311
Calcitriol Treatment Is Not Effective in Postmenopausal Osteoporosis
Ott, S. M., & Chesnut, C. H. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-4-267 · Cited by 308
Flicker, L., MacInnis, R. J., Stein, M. S., Scherer, S. C., Mead, K. E., Nowson, C. A., Thomas, J., Lowndes, C., Hopper, J. L., & Wark, J. D. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.00468.x · Cited by 305
Riggs, B. L., O'Fallon, W. M., Muhs, J., O'Connor, M. K., Kumar, R., & Melton, L. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.2.168 · Cited by 303
Papadimitropoulos, E., Wells, G., Shea, B., Gillespie, W., Weaver, B., Zytaruk, N., Cranney, A., Adachi, J., Tugwell, P., Josse, R., et al. (2002) · Endocrine Reviews · doi:10.1210/er.2001-8002 · Cited by 302
Jamal, S. A., Bauer, D. C., Ensrud, K. E., Cauley, J. A., Hochberg, M., Ishani, A., & Cummings, S. R. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070112 · Cited by 301
Offenbaecher, M., Bondy, B., Jonge, S. D., Glatzeder, K., Kr�ger, M., Schoeps, P., & Ackenheil, M. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199911)42:11<2482::aid-anr27>3.0.co;2-b · Cited by 298
Stevenson, M., Lloyd Jones, M., De Nigris, E., Brewer, N., Davis, S., & Oakley, J. (2005) · Health Technology Assessment · doi:10.3310/hta9220 · Cited by 295 · cited 8×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialBisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases
Filleul, O., Crompot, E., & Saussez, S. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0907-7 · Cited by 295
Schwartz, A. V., Bauer, D. C., Cummings, S. R., Cauley, J. A., Ensrud, K. E., Palermo, L., Wallace, R. B., Hochberg, M. C., Feldstein, A. C., Lombardi, A., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.11 · Cited by 289
VI. Meta-Analysis of Calcitonin for the Treatment of Postmenopausal Osteoporosis
Cranney, A., Tugwell, P., Zytaruk, N., Robinson, V., Weaver, B., Shea, B., Wells, G., Adachi, J., Waldegger, L., Guyatt, G., et al. (2002) · Endocrine Reviews · doi:10.1210/er.2001-6002 · Cited by 286
III. Meta-Analysis of Risedronate for the Treatment of Postmenopausal Osteoporosis
Cranney, A., Tugwell, P., Adachi, J., Weaver, B., Zytaruk, N., Papaioannou, A., Robinson, V., Shea, B., Wells, G., & Guyatt, G. (2002) · Endocrine Reviews · doi:10.1210/er.2001-3002 · Cited by 281
Randomized Controlled Trial of Calcium in Healthy Older Women
Reid, I. R., Mason, B., Horne, A., Ames, R., Reid, H. E., Bava, U., Bolland, M. J., & Gamble, G. D. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.02.038 · Cited by 281
Prevention of Nonvertebral Fractures by Alendronate: A Meta-analysis
Karpf, D. B. (1997) · JAMA · doi:10.1001/jama.1997.03540380073035 · Cited by 281
Bisphosphonate Associated Osteonecrosis of the Jaw
KHAN, A. A., SÁNDOR, G. K. B., DORE, E., MORRISON, A. D., ALSAHLI, M., AMIN, F., PETERS, E., HANLEY, D. A., CHAUDRY, S. R., LENTLE, B., et al. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.080759 · Cited by 280
Murad, M. H., Drake, M. T., Mullan, R. J., Mauck, K. F., Stuart, L. M., Lane, M. A., Abu Elnour, N. O., Erwin, P. J., Hazem, A., Puhan, M. A., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3060 · Cited by 277
Alendronate and Estrogen Effects in Postmenopausal Women with Low Bone Mineral Density
Bone, H. G. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.720 · Cited by 277 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialGreen, J., Czanner, G., Reeves, G., Watson, J., Wise, L., & Beral, V. (2010) · BMJ · doi:10.1136/bmj.c4444 · Cited by 275
Papapoulos, S., Lippuner, K., Roux, C., Lin, C. J. F., Kendler, D. L., Lewiecki, E. M., Brandi, M. L., Czerwiński, E., Franek, E., Lakatos, P., et al. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3234-7 · Cited by 274 · cited 1×
“A post hoc analysis of the open-label extension of FREEDOM (Fracture Reduction Evaluation of Denosumab in Osteoporosis every 6 Months) confirmed 2 events of atypical femoral fracture and 8 events of osteonecrosis of the jaw through 8 years of denosumab therapy (100).”
MethodBone-Density Testing Interval and Transition to Osteoporosis in Older Women
Gourlay, M. L., Fine, J. P., Preisser, J. S., May, R. C., Li, C., Lui, L.-Y., Ransohoff, D. F., Cauley, J. A., & Ensrud, K. E. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107142 · Cited by 273
Nakamura, T., Sugimoto, T., Nakano, T., Kishimoto, H., Ito, M., Fukunaga, M., Hagino, H., Sone, T., Yoshikawa, H., Nishizawa, Y., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3479 · Cited by 268
McClung, M., Clemmesen, B., Daifotis, A., Gilchrist, N. L., Eisman, J., Weinstein, R. S., El Hajj Fuleihan, G., Reda, C., Yates, A. J., & Ravn, P. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-4-199802150-00001 · Cited by 268 · cited 8×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialMichaelsson, K., Melhus, H., Warensjo Lemming, E., Wolk, A., & Byberg, L. (2013) · BMJ · doi:10.1136/bmj.f228 · Cited by 264
Ebrahim, S., Thompson, P. W., Baskaran, V., & Evans, K. (1997) · Age and Ageing · doi:10.1093/ageing/26.4.253 · Cited by 261
Delmas, P. D., Adami, S., Strugala, C., Stakkestad, J. A., Reginster, J., Felsenberg, D., Christiansen, C., Civitelli, R., Drezner, M. K., Recker, R. R., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21918 · Cited by 258
Crandall, C. J., Newberry, S. J., Diamant, A., Lim, Y.-W., Gellad, W. F., Booth, M. J., Motala, A., & Shekelle, P. G. (2014) · Annals of Internal Medicine · doi:10.7326/m14-0317 · Cited by 254 · cited 16×
“The AHRQ systematic review was peer-reviewed and posted on the AHRQ website for public comments.”
BackgroundMethodInfluentialBone, H. G., Chapurlat, R., Brandi, M.-L., Brown, J. P., Czerwiński, E., Krieg, M.-A., Mellström, D., Radominski, S. C., Reginster, J.-Y., Resch, H., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1597 · Cited by 254
Sorensen, O. H., Crawford, G. M., Mulder, H., Hosking, D. J., Gennari, C., Mellstrom, D., Pack, S., Wenderoth, D., Cooper, C., & Reginster, J.-Y. (2003) · Bone · doi:10.1016/s8756-3282(02)00946-8 · Cited by 254 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialBlack, D. M., Reid, I. R., Cauley, J. A., Cosman, F., Leung, P. C., Lakatos, P., Lippuner, K., Cummings, S. R., Hue, T. F., Mukhopadhyay, A., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2442 · Cited by 253
Otto, S., Schreyer, C., Hafner, S., Mast, G., Ehrenfeld, M., Stürzenbaum, S., & Pautke, C. (2012) · Journal of Cranio-Maxillofacial Surgery · doi:10.1016/j.jcms.2011.05.003 · Cited by 252
Xiao, Q., Murphy, R. A., Houston, D. K., Harris, T. B., Chow, W.-H., & Park, Y. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.3283 · Cited by 250
Smith, M. R., Fallon, M. A., Lee, H., & Finkelstein, J. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032058 · Cited by 248 · cited 1×
“92) (122, 341, 345, 347) and cerebrovascular death (OR, 1.”
Siris, E. S., Harris, S. T., Eastell, R., Zanchetta, J. R., Goemaere, S., Diez-Perez, A., Stock, J. L., Song, J., Qu, Y., Kulkarni, P. M., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050509 · Cited by 243
Greenspan, S. L., Parker, R. A., Ferguson, L., Rosen, H. N., Maitland-Ramsey, L., & Karpf, D. B. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.9.1431 · Cited by 238 · cited 8×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialPeacock, M. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.9.3011 · Cited by 235
Komulainen, M. H., Kröger, H., Tuppurainen, M. T., Heikkinen, A.-M., Alhava, E., Honkanen, R., & Saarikoski, S. (1998) · Maturitas · doi:10.1016/s0378-5122(98)00085-1 · Cited by 235
Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment
Miller, P. D., Schwartz, E. N., Chen, P., Misurski, D. A., & Krege, J. H. (2007) · Osteoporosis International · doi:10.1007/s00198-006-0189-8 · Cited by 235
Miller, P. D., Chines, A. A., Christiansen, C., Hoeck, H. C., Kendler, D. L., Lewiecki, E. M., Woodson, G., Levine, A. B., Constantine, G., & Delmas, P. D. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.071206 · Cited by 234
Qaseem, A., Snow, V., Owens, D. K., Shekelle, P., & for the Clinical Guidelines Committee of the American College of Physicians (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-3-201008030-00010 · Cited by 233 · cited 10×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundMethodInfluentialSelf-citationJohnell, O. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.3.985 · Cited by 230
Watts, N. B., Cooper, C., Lindsay, R., Eastell, R., Manhart, M. D., Barton, I. P., van Staa, T.-P., & Adachi, J. D. (2004) · Journal of Clinical Densitometry · doi:10.1385/jcd:7:3:255 · Cited by 229
Meyer, H. E., Smedshaug, G. B., Kvaavik, E., Falch, J. A., Tverdal, A., & Pedersen, J. I. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.4.709 · Cited by 226
Harwood, R. H., Sahota, O., Gaynor, K., Masud, T., & Hosking, D. J. (2004) · Age and Ageing · doi:10.1093/ageing/afh002 · Cited by 225
Exposure to Oral Bisphosphonates and Risk of Esophageal Cancer
Cardwell, C. R., Abnet, C. C., Cantwell, M. M., & Murray, L. J. (2010) · JAMA · doi:10.1001/jama.2010.1098 · Cited by 224
Orimo, H., Shiraki, M., Hayashi, Y., Hoshino, T., Onaya, T., Miyazaki, S., Kurosawa, H., Nakamura, T., & Ogawa, N. (1994) · Calcified Tissue International · doi:10.1007/bf00305521 · Cited by 222
Mortensen, L., Charles, P., Bekker, P. J., Digennaro, J., & Johnston, C. C. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.2.4586 · Cited by 220 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialGallagher, J. C., & Goldgar, D. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-9-649 · Cited by 217
Combination Treatment with Estrogen and Calcitriol in the Prevention of Age-Related Bone Loss
Gallagher, J. C., Fowler, S. E., Detter, J. R., & Sherman, S. S. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7703 · Cited by 216
Johnston, C. C., Bjarnason, N. H., Cohen, F. J., Shah, A., Lindsay, R., Mitlak, B. H., Huster, W., Draper, M. W., Harper, K. D., Heath, H., et al. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.22.3444 · Cited by 211
Wells, G. A., Cranney, A., Peterson, J., Boucher, M., Shea, B., Welch, V., Coyle, D., & Tugwell, P. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004523.pub3 · Cited by 211 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialVitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup.
Adachi, J. D., Wg, B., Bianchi, F. A., Cividino, A. A., Pillersdorf, S., Sebaldt, R. J., Tugwell, P., Gordon, M., Steele, M., Webber, C., et al. (1996) · PubMed · Cited by 209
Alendronate or Alfacalcidol in Glucocorticoid-Induced Osteoporosis
de Nijs, R. N. J., Jacobs, J. W. G., Lems, W. F., Laan, R. F. J., Algra, A., Huisman, A.-M., Buskens, E., de Laet, C. E. D., Oostveen, A. C. M., Geusens, P. P. M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053569 · Cited by 208
Fogelman, I., Ribot, C., Smith, R., Ethgen, D., Sod, E., & Reginster for the bmd-mn Study Grou, J.-Y. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.5.6603 · Cited by 198 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialBolton-Smith, C., McMurdo, M. E., Paterson, C. R., Mole, P. A., Harvey, J. M., Fenton, S. T., Prynne, C. J., Mishra, G. D., & Shearer, M. J. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070116 · Cited by 196
Boonen, S., Orwoll, E. S., Wenderoth, D., Stoner, K. J., Eusebio, R., & Delmas, P. D. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081214 · Cited by 193 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialLaw, M., Withers, H., Morris, J., & Anderson, F. (2006) · Age and Ageing · doi:10.1093/ageing/afj080 · Cited by 191
Effect of Ibandronate on Bone Loss and Renal Function after Kidney Transplantation
GROTZ, W., NAGEL, C., POESCHEL, D., CYBULLA, M., PETERSEN, K.-G., UHL, M., STREY, C., KIRSTE, G. D., OLSCHEWSKI, M., REICHELT, A., et al. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1271530 · Cited by 190
Dose-Response Relationships for Alendronate Treatment in Osteoporotic Elderly Women1
Bone, H. G., Downs, R. W., Tucci, J. R., Harris, S. T., Weinstein, R. S., Licata, A. A., McClung, M. R., Kimmel, D. B., Gertz, B. J., Hale, E., et al. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3682 · Cited by 189
Harris, S. T., Blumentals, W. A., & Miller, P. D. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x253717 · Cited by 186
SINAKI, M., WAHNER, H. W., OFFORD, K. P., & HODGSON, S. F. (1989) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)61748-0 · Cited by 182
Dukas, L., Bischoff, H. A., Lindpaintner, L. S., Schacht, E., Birkner‐binder, D., Damm, T. N., Thalmann, B., & Stähelin, H. B. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52060.x · Cited by 181
Qaseem, A., Snow, V., Shekelle, P., Hopkins, R., Forciea, M. A., Owens, D. K., & Clinical Efficacy Assessment Subcommittee of the American College of Physicians (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-6-200809160-00007 · Cited by 180
Self-citationPapapoulos, S. E., Quandt, S. A., Liberman, U. A., Hochberg, M. C., & Thompson, D. E. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1725-z · Cited by 175 · cited 8×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRecker, R., Stakkestad, J. A., Chesnut, C. H., Christiansen, C., Skag, A., Hoiseth, A., Ettinger, M., Mahoney, P., Schimmer, R. C., & Delmas, P. D. (2004) · Bone · doi:10.1016/j.bone.2004.01.008 · Cited by 172 · cited 1×
“29]) (92, 310), and zoledronic acid is associated with adverse effects including atrial fibrillation (OR, 1.”
BackgroundCan health visitors prevent fractures in elderly people?
Vetter, N. J., Lewis, P. A., & Ford, D. (1992) · BMJ · doi:10.1136/bmj.304.6831.888 · Cited by 172
Nakamura, T., Matsumoto, T., Sugimoto, T., Hosoi, T., Miki, T., Gorai, I., Yoshikawa, H., Tanaka, Y., Tanaka, S., Sone, T., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4175 · Cited by 170 · cited 1×
“One Japanese trial and its 1-year open-label extension study included postmenopausal osteoporotic women with prevalent radiographic vertebral fractures and showed that denosumab protected against radiographic vertebral fractures (101, 109).”
BackgroundEfficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study
Ringe, J. D., Faber, H., Farahmand, P., & Dorst, A. (2006) · Rheumatology International · doi:10.1007/s00296-005-0004-4 · Cited by 169 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialCalcium Intake and Cardiovascular Disease Risk: An Updated Systematic Review and Meta-analysis
Chung, M., Tang, A. M., Fu, Z., Wang, D. D., & Newberry, S. J. (2016) · Annals of Internal Medicine · doi:10.7326/m16-1165 · Cited by 166
for the Bazedoxifene Study Group, Silverman, S. L., Chines, A. A., Kendler, D. L., Kung, A. W. C., Teglbjærg, C. S., Felsenberg, D., Mairon, N., Constantine, G. D., & Adachi, J. D. (2012) · Osteoporosis International · doi:10.1007/s00198-011-1691-1 · Cited by 165
Avenell, A., Gillespie, W. J., Gillespie, L. D., & O'Connell, D. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000227.pub2 · Cited by 165
Watts, N. B., Geusens, P., Barton, I. P., & Felsenberg, D. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050814 · Cited by 164
Reid, D. M., Adami, S., Devogelaer, J.-P., & Chines, A. A. (2001) · Calcified Tissue International · doi:10.1007/s00223-001-1060-8 · Cited by 160 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialSafety and Adverse Effects Associated With Raloxifene: Multiple Outcomes of Raloxifene Evaluation
Grady, D., Ettinger, B., Moscarelli, E., Plouffe, L., Sarkar, S., Ciaccia, A., & Cummings, S. (2004) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000137349.79204.b8 · Cited by 159 · cited 1×
“92) (122, 341, 345, 347) and cerebrovascular death (OR, 1.”
Crawford, B. A. L., Kam, C., Pavlovic, J., Byth, K., Handelsman, D. J., Angus, P. W., & McCaughan, G. W. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-4-200602210-00005 · Cited by 158
Chen, P., Miller, P. D., Delmas, P. D., Misurski, D. A., & Krege, J. H. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060802 · Cited by 158
Greenspan, S. L., Resnick, N. M., & Parker, R. A. (2003) · JAMA · doi:10.1001/jama.289.19.2525 · Cited by 156 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialBoonen, S., Laan, R., Barton, I. P., & Watts, N. B. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1945-x · Cited by 155 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialBrown, J. P., Roux, C., Törring, O., Ho, P., Jensen, J. B., Gilchrist, N. L., Recknor, C. P., Austin, M., Wang, A., Grauer, A., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1808 · Cited by 153
The effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: a meta-analysis
Jackson, C., Gaugris, S., Sen, S. S., & Hosking, D. J. (2007) · QJM · doi:10.1093/qjmed/hcm005 · Cited by 153
Ravn, P., Clemmesen, B., Riis, B. J., & Christiansen, C. (1996) · Bone · doi:10.1016/s8756-3282(96)00229-3 · Cited by 151
Grbic, J. T., Landesberg, R., Lin, S., Mesenbrink, P. G., Reid, I. R., Leung, P., Casas, N., Recknor, C. P., Hua, Y., Delmas, P. D., et al. (2008) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2008.0017 · Cited by 150
The Effect of Raloxifene Treatment in Postmenopausal Women with CKD
Ishani, A., Blackwell, T., Jamal, S. A., Cummings, S. R., & Ensrud, K. E. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007050555 · Cited by 148
Otto, S., Abu-Id, M. H., Fedele, S., Warnke, P. H., Becker, S. T., Kolk, A., Mücke, T., Mast, G., Köhnke, R. H., Volkmer, E., et al. (2010) · Journal of Cranio-Maxillofacial Surgery · doi:10.1016/j.jcms.2010.05.009 · Cited by 147
Bonnick, S. L., Saag, K. G., Kiel, D. P., McClung, M. R., Hochberg, M. C., Burnett‐Bowie, S. M., Sebba, A. I., Kagan, R., Chen, E., Thompson, D. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2602 · Cited by 145
Nickélsen, T., Lufkin, E. G., Riggs, B. L., Cox, D. A., & Crook, T. H. (1999) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(98)00041-9 · Cited by 144
Gallagher, J. C., Genant, H. K., Crans, G. G., Vargas, S. J., & Krege, J. H. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0826 · Cited by 144
Adámi, S., Passeri, M., Ortolani, S., Broggini, M., Carratelli, L., Caruso, I., Gandolini, G., Gnessi, L., Laurenzi, M. W., Lombardi, A., et al. (1995) · Bone · doi:10.1016/s8756-3282(95)00262-6 · Cited by 142 · cited 8×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialZein, C. O., Jorgensen, R. A., Clarke, B., Wenger, D. E., Keach, J. C., Angulo, P., & Lindor, K. D. (2005) · Hepatology · doi:10.1002/hep.20866 · Cited by 142
Matsumoto, T., Miki, T., Hagino, H., Sugimoto, T., Okamoto, S., Hirota, T., Tanigawara, Y., Hayashi, Y., Fukunaga, M., Shiraki, M., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2552 · Cited by 142 · cited 1×
“One study showed increased risk for hypercalciuria with vitamin D supplementation (356).”
BackgroundFreemantle, N., Cooper, C. C., Díez‐Pérez, A., Gitlin, M. D., Radcliffe, H.-S., Shepherd, S., & Roux, C. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2068-9 · Cited by 141
Orimo, H., Shiraki, M., Hayashi, T., & Nakamura, T. (1987) · PubMed · Cited by 140
Vescovi, P., Campisi, G., Fusco, V., Mergoni, G., Manfredi, M., Merigo, E., Solazzo, L., Gabriele, M., Gaeta, G. M., Favia, G., et al. (2011) · Oral Oncology · doi:10.1016/j.oraloncology.2010.11.007 · Cited by 140
Richy, F., Schacht, E., Bruyere, O., Ethgen, O., Gourlay, M., & Reginster, J.-Y. (2005) · Calcified Tissue International · doi:10.1007/s00223-004-0005-4 · Cited by 137
Ensrud, K. E., Stock, J. L., Barrett-Connor, E. L., Grady, D. G., Mosca, L. J., Khaw, K., Zhao, Q., Agnusdei, D., & Cauley, J. A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070904 · Cited by 137
Richy, F., Ethgen, O., Bruyere, O., & Reginster, J.-Y. (2004) · Osteoporosis International · doi:10.1007/s00198-003-1570-5 · Cited by 136
Boonen, S., Black, D. M., Colon-Emeric, C. S., Eastell, R., Magaziner, J. S., Eriksen, E. F., Mesenbrink, P. G., Haentjens, P., & Lyles, K. W. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2009.02673.x · Cited by 136
Schwartz, A. V., Schafer, A. L., Grey, A. B., Vittinghoff, E., Palermo, L., Lui, L., Wallace, R. B., Cummings, S. R., Black, D. M., Bauer, D. C., et al. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1865 · Cited by 135
Bisphosphonates and Risk of Cardiovascular Events: A Meta-Analysis
Kim, D. H., Rogers, J. R., Fulchino, L. A., Kim, C. A., Solomon, D. H., & Kim, S. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122646 · Cited by 135 · cited 1×
“In contrast, a recent meta-analysis concluded that there is no significant association between oral or intravenous bisphosphonate use and total cardiovascular events, stroke, myocardial infarction, or cardiovascular death (287).”
ResultBoonen, S., Marín, F., Mellström, D., Xie, L., Desaiah, D., Krege, J. H., & Rosen, C. J. (2006) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2006.00695.x · Cited by 134
Chapurlat, R. D., Palermo, L., Ramsay, P., & Cummings, S. R. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1770-7 · Cited by 133
Gaudin, E., Seidel, L., Baćević, M., Rompen, E., & Lambert, F. (2015) · Journal Of Clinical Periodontology · doi:10.1111/jcpe.12455 · Cited by 133
Boutsen, Y., Jamart, J., Esselinckx, W., Stoffel, M., & Devogelaer, J. (1997) · Calcified Tissue International · doi:10.1007/s002239900334 · Cited by 132
Lyons, R. A., Johansen, A., Brophy, S. T., Newcombe, R. G., Phillips, C. J., Lervy, B., Evans, R., Wareham, K., & Stone, M. D. (2007) · Osteoporosis International · doi:10.1007/s00198-006-0309-5 · Cited by 130
Calcium and Vitamin D Supplementation Increases Spinal BMD in Healthy, Postmenopausal Women
Bæksgaard, L., Andersen, K. P., & Hyldstrup, L. (1998) · Osteoporosis International · doi:10.1007/s001980050062 · Cited by 127
Research works printed but not linked: 25
- Bonnick S, 1998, Bone, 23, S476
- 10.1210/jcem.85.2.6393 · doi:10.1210/jcem.85.2.6393 · Paper page
- 10.1185/030079903125002009 · DOI
- McClung M, 1998, Osteoporos Int, 8, 111
- Chao M, 2013, Pak J Med Sci, 29, 1381
- Lippuner K, 2013, Osteoporosis Int, 24, S39
- Palacios S, 2013, Osteoporosis Int, 24, S299
- Papapoulos S, 2013, Osteoporosis Int, 24, S45
- 10.1359/jbmr.2003.18.1.9 · DOI · Paper page
- 10.1210/jcem.85.9.6836 · doi:10.1210/jcem.85.9.6836 · Paper page
- Adachi JD, 1996, J Rheumatol, 23, 995
- Aloia JF, 1985, J Lab Clin Med, 106, 630
- Caniggia A, 1984, Acta Vitaminol Enzymol, 6, 117
- Geusens P, 1986, Bone Miner, 1, 347
- Jensen GF, 1985, Clin Orthop Relat Res, 215
- Menczel J, 1994, Clin Orthop Relat Res, 241
- Orimo H, 1987, Bone Miner, 3, 47
- Muscoso E, 2004, Eur Rev Med Pharmacol Sci, 8, 97
- Migliore A, 2013, Eur Rev Med Pharmacol Sci, 17, 658
- Almăşan HA, 2011, Rom J Morphol Embryol, 52, 1233
- 10.1056/nejmoa011807 · DOI · Paper page
- Krohn K, 2014, Osteoporosis Int, 25, S61, 10.1007/s00198-013-2525-0 · DOI
- 10.1210/jcem.87.3.8325 · doi:10.1210/jcem.87.3.8325 · Paper page
- Zheng S, 2003, Chin Med J (Engl), 116, 1127
- Liu JL, 2004, Chin Med J (Engl), 117, 1029
Cited by
The clinician's guide to prevention and treatment of osteoporosis
LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-05900-y · Cited by 1,487
Wu, A.-M., Bisignano, C., James, S. L., Abady, G. G., Abedi, A., Abu-Gharbieh, E., Alhassan, R. K., Alipour, V., Arabloo, J., Asaad, M., et al. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00172-0 · Cited by 1,291
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
Eastell, R., Rosen, C. J., Black, D. M., Cheung, A. M., Murad, M. H., & Shoback, D. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00221 · Cited by 868
Osteoporosis: A Review of Treatment Options.
Tu, K. N., Lie, J. D., Wan, C. K. V., Cameron, M., Austel, A. G., Nguyen, J. K., Van, K., & Hyun, D. (2018) · PubMed · Cited by 735
Metadata
- Authors
- Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians*
- Affiliations
- Yale University (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2017-06-06
- Volume
- 166
- Issue
- 11
- Pages
- 818-839
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2614075773
- Cited by
- 676
- References
- 368
- Citations by year
- 2026: 33 · 2025: 53 · 2024: 65 · 2023: 85 · 2022: 82 · 2021: 81 · 2020: 95 · 2019: 75 · 2018: 70 · 2017: 35
- FWCI
- 83.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- osteoporosis, osteopenia, fracture prevention, pharmacotherapy, bisphosphonates, denosumab, zoledronic acid, risedronate, alendronate, hormone replacement therapy, raloxifene, calcium and vitamin D supplementation, treatment duration, hip fracture
- MeSH terms
- Denosumab, Bone Diseases, Metabolic, Calcium, Dietary, Diphosphonates, Female, Humans, Male, Osteoporosis, Risk Factors, Vitamin D, Exercise, Osteoporosis, Postmenopausal, Estrogen Replacement Therapy, Teriparatide, Raloxifene Hydrochloride, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.